Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena)
Case report
OA: bronze
CC0
⤵ 1 in-corpus citation
AI-generated summary
This report details a case of endometrial cancer in a postmenopausal woman using a levonorgestrel-releasing intrauterine system for menorrhagia, prompting discussion on management implications.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The levonorgestrel-releasing intrauterine system (LNGIUS) Mirena has been licensed as a contraceptive in the UK since 1995. In 2002 Mirena became licensed also for the management of idiopathic menorrhagia and in 2004 the product licence was extended further to use for protection to prevent endometrial hyperplasia in women receiving oestrogen replacement therapy. We report a case of primary endometrioid endometrial carcinoma diagnosed in a postmenopausal woman who had a LNG-IUS inserted 4 years previously for treatment of perimenopausal menorrhagia and we discuss the implications for management of women presenting with perimenopausal menorrhagia. (excerpt)
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (1)
References (8)
- Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia via openalex
- W2031785143 via openalex
- W2040706253 via openalex
- W2041983304 via openalex
- W2070900245 via openalex
- W2095603025 via openalex
- W1994038216 via openalex
- W2101734337 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:03:51.313027+00:00
License: CC0
· commercial use OK